13 Aug 2021 --- Debut Biotech, a biomanufacturing platform harnessing cell-free enzymes, has raised US$22.6 million in series A financing, led by Material Impact, a US-based venture firm. Debut Biotech will use the funds to commercialize ingredients developed from its proprietary cell-free biomanufacturing platform. It has applications across various industries, including food and wellness products.
